Later today at #ACR23 at 4pm See Ab#2545 on IV secukinumab for AxSpA Read about it now on @RheumNow: https://t.co/s9IinpVxgR

The Fallacy of Biologic Treatment to Prevent RA It is time to stop fooling ourselves that we can prevent RA with our existing biologic agents. #ACR23 https://t.co/qHMW4HGkk2 https://t.co/l2Tn7hGtY3

• The Fallacy of Biologic Treatment to Prevent Rheumatoid Arthritis | RheumNow

Gender differences in switching biologics in PsA pts Women had higher biologic switch rates, mainly due to lack of efficacy Other gender specific factors include gestational reasons and different sociodemographic features @RheumNow #ACR23 Abs#2247 https://t.co/mLm183fCBw

If we're to summarize the challenges to making for CAR-T therapy work in a given disease, this is it: Dr. Chyi-Song Hsieh ⁦@WUSTL #ACR23 @RheumNow https://t.co/raoHtrJ25S

Vaccination appears to be effective and safe post CAR-T treatment. This sets the stage for better understanding of the patient experience. Dr. Schett #ACR23 @RheumNow https://t.co/OQCNTt5wPh

#ACR23 highlights from PlenaryII 🙉#RA #ILD seems that #TNFi is equal to other bDMARDs - was thought to worsen /cause it. 🙉Septra should be given with #rituximab and #steroids in #GCA to prevent #infections not just #PJP #ACR23 @RheumNow @ACRheum #ACRbest

#Infection rates are equal in #RWD #real #world #data using #biosimilars compared to previous use of #originators. BC database #0970 #ACR23 ⁦@RheumNow⁩ ⁦@ACRheum⁩ #arthritisresearchcanada #ARC https://t.co/eVSPgVfmQG